Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A‐catalysed hydroxylation by sulfaphenazole

The aim of this study was to characterize the human cytochrome P450s (CYPs) involved in oxidative bioactivation of flucloxacillin to 5‐hydroxymethyl flucloxacillin, a metabolite with high cytotoxicity towards biliary epithelial cells.

• Publication year

  2018

• Venue

  British Journal of Pharmacology

• Publication date

  2018-12-26

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/bph.14548PMID 30447161PMCID 6329626
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Flucloxacillin–warfarin interaction: an under‐appreciated phenomenon

  2018cited by this paper
• Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers

  2018cited by this paper
• Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals.

  2018cited by this paper
• A combined computational and experimental study on selective flucloxacillin hydroxylation by cytochrome P450 BM3 variants.

  2018cited by this paper
• Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A‐catalysed hydroxylation by sulfaphenazole

  2018cited by this paper
• THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes

  2017cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

  2017cited by this paper
• Pharmacokinetics of flucloxacillin and its metabolites in patients with renal failure: Impact on liver toxicity
.

  2017cited by this paper
• Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations

  2017cited by this paper
• Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib

  2016cited by this paper
• The chemical, genetic and immunological basis of idiosyncratic drug–induced liver injury

  2015cited by this paper
• T cells infiltrate the liver and kill hepatocytes in HLA-B(∗)57:01-associated floxacillin-induced liver injury.

  2014cited by this paper
• Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis

  2014influential reference
• HLA Haplotype Determines Hapten or p-i T Cell Reactivity to Flucloxacillin

  2013cited by this paper
• Human leukocyte antigen (HLA)‐B*57:01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury

  2013influential reference
• Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities

  2012cited by this paper
• A Simplified Oral Flucloxacillin Absorption Test for Patients Requiring Long-Term Treatment

  2012cited by this paper
• Interaction of flucloxacillin and quinidine

  2011cited by this paper
• Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

  2011cited by this paper
• HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

  2009influential reference
• Characterisation of flucloxacillin and 5‐hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo

  2009cited by this paper
• Flucloxacillin-induced liver injury.

  2008cited by this paper
• Flucloxacillin-associated hepatic injury.

  2008cited by this paper
• Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin

  2007cited by this paper
• Idiosyncratic drug reactions: current understanding.

  2007cited by this paper
• Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.

  2006cited by this paper
• CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles

  2006influential reference
• Modelling atypical CYP3A4 kinetics: principles and pragmatism.

  2005cited by this paper
• Dicloxacillin and flucloxacillin: Pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration

  2005cited by this paper
• CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele

  2005cited by this paper
• Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.

  2005cited by this paper
• Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions.

  2005influential reference
• Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.

  2005influential reference
• Acute and clinically relevant drug-induced liver injury: a population based case-control study.

  2004cited by this paper
• The metabolic disposition of flucloxacillin in patients with impaired kidney function

  2004cited by this paper
• In vitro and pharmacophore insights into CYP3A enzymes.

  2003cited by this paper
• Membrane properties induced by anionic phospholipids and phosphatidylethanolamine are critical for the membrane binding and catalytic activity of human cytochrome P450 3A4.

  2003cited by this paper
• Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

  2002cited by this paper
• Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine*

  2002cited by this paper
• Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes.

  2001influential reference
• Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

  2000cited by this paper
• In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

  2000cited by this paper
• The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis.

  1999cited by this paper
• Pharmacokinetics and Bioavailability of Flucloxacillin in Elderly Hospitalized Patients

  1995influential reference
• Dicloxacillin and flucloxacillin: Pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration

  1995cited by this paper
• Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver.

  1994cited by this paper
• Risk factors for development of flucloxacillin associated jaundice.

  1993cited by this paper
• Flucloxacillin Induced Liver Disease: Histopathological Findings At Biopsy And Autopsy

  1993cited by this paper
• Cholestatic Hepatitis Associated with Flucloxacillin

  1993cited by this paper
• Pharmacokinetics of amoxicillin and flucloxacillin following the simultaneous intravenous administration of 4 g and 1 g, respectively

  1983cited by this paper
• Flucloxacillin, a New Isoxazolyl Penicillin, Compared with Oxacillin, Cloxacillin, and Dicloxacillin

  1970cited by this paper

• Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes

  2024cites this paper
• Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review

  2024cites this paper
• Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on Roussel Uclaf Causality Assessment Method and HLA B*57:01 Genotype: From Metabolic CYP 3A4/3A7 to Immune Mechanisms

  2024influential citation
• Green electrosynthesis of drug metabolites

  2023cites this paper
• Oxidative Stress-induced liver damage and remodeling of the liver vasculature.

  2023cites this paper
• Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes

  2023cites this paper
• Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations

  2023cites this paper
• A comparative review of the activity of enzymes of the cytochrome P450 system in humans and laboratory animals. Prognostic value of preclinical models in vivo

  2022cites this paper
• Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism

  2022cites this paper
• Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening

  2021cites this paper
• Drug‐Metabolism Enzymes and Transporter Activities as Risk Factors of Selected Marketed Drugs Associated with Drug‐Induced Fatalities

  2021cites this paper
• Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study

  2020cites this paper
• Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues

  2020cites this paper
• Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents

  2020cites this paper
• Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A‐catalysed hydroxylation by sulfaphenazole

  2018cites this paper
• Flucloxacillin–warfarin interaction: an under‐appreciated phenomenon

  2018cites this paper
• Meet Our Associate Editor

  2017cites this paper
• Stress Responses and Cellular Crosstalk in the Pathogenesis of Liver Disease Theme Issue REVIEW Oxidative Stress e Induced Liver Damage and Remodeling of the Liver Vasculature

  year unknowncites this paper